Clinuvel (ASX:CUV) share price falls despite positive update

The Clinuvel Pharmaceuticals Limited (ASX: CUV) share price is tumbling in early morning trade despite releasing an update to market.

| More on:
laboratory microscope

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Clinuvel Pharmaceuticals Limited (ASX: CUV) share price is tumbling in early morning trade. This comes despite releasing an update to the market. At the time of writing, the biopharmaceutical company's shares are swapping hands for $27.99, down 2.3%.

What did Clinuvel announce?

The Clinuvel share price is being weighed down by investors despite the company's positive announcement.

According to this morning's release, Clinuvel advised that it has now expanded its DNA repair program. The clinical trials will now evaluate afamelanotide in skin cells which have been damaged by ultraviolet (UV) and sun exposure. Patients suffering from rare diseases such as XP-V and XP-C will be included in the study.

Following an agreement by clinical and academic experts, Clinuvel will seek to evaluate the safety and efficacy of afamelanotide.

The company explained how UV radiation damages skin cells, causing defects of the DNA helix. It noted that if left unrepaired, chemical changes to DNA could replicate, thus leading to irreversible damage (photoaging). Continued exposure could also progress to skin cancer, including melanoma.

XP patients in particular have genetic defects that contain impaired DNA repair processes. Thus, leading to an extreme risk of skin cancer. This is unlike most individuals who are able to protect themselves for UV damage and repair cellular DNA.

Afamelanotide is an active ingredient in SCENESSE. Moreover, it improves the function of skin cells that have been damaged. Clinuvel hopes that conducting trials with afamelanotide will produce the first positive results sometime this year.

Management commentary

Clinuvel chief scientific officer Dr. Dennis Wright commented:

XP patients are at extreme risk of skin cancer – up to 10,000 times that of the general population – due to their inability to repair damage caused by UV and sunlight, known as photodamage.

Afamelanotide has been shown to protect skin from UV and light, and repair photodamage. We are now working to confirm this concept in clinical trials with both XP patients and healthy volunteers.

About the Clinuvel share price

The Clinuvel share price has gained over 60% since this time last year. Currently, the share price is up 25% year-to-date. It's worth noting that the company's shares reached a 52-week high of $28.80 earlier this month.

Based on valuation grounds, Clinuvel commands a market capitalisation of around $1.38 billion, with 49.4 million shares on issue.

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Market News

Person pointing finger on on an increasing graph which represents a rising share price.
Broker Notes

These ASX shares could rise 20% to 30%

Big returns could be on the cards for buyers of these shares according to analysts.

Read more »

Modern accountant woman in a light business suit in modern green office with documents and laptop.
Broker Notes

All about the momentum: Which ASX 200 stocks does Macquarie currently favour?

These stocks have strong positive momentum.

Read more »

A graphic showing a businessman running up a white upwards rising arrow symbolising the soaring Magellan share price today
Share Gainers

CBA shares hit another all-time high. Can they surpass $200 in 2025?

CBA shares have a tailwind pushing up their price that has nothing directly to do with the bank's business performance.

Read more »

a young woman raises her hands in joyful celebration as she sits at her computer in a home environment.
Share Gainers

Why Alliance Aviation, Cogstate, Collins Foods, and Findi shares are roaring higher today

These shares are having a good session on Tuesday. Let's find out why.

Read more »

Frustrated stock trader screaming while looking at mobile phone, symbolising a falling share price.
Share Fallers

Why APA, DroneShield, EOS, and Woodside shares are tumbling today

These shares are missing out on the good times on Tuesday.

Read more »

Woman checking out new iPads.
Broker Notes

'Lock in profits at these levels': Expert's verdict on 2 ASX 200 shares

Tony Locantro of Alto Capital says it might be time to take profits on these high-flying ASX 200 shares.

Read more »

asx share price growth represented by hand holding hourglass surrounded by dollar signs
Opinions

'Patience isn't passive': Expert reveals 2 ASX shares his team won and lost on

They say patience is a virtue. This asset manager says it can also determine your investment success.

Read more »

A pilot stands in an empty passenger cabin smiling with his arms crossed looking excited
Travel Shares

Virgin Australia shares take flight on ASX return after IPO

The airline's long-awaited return has started strongly.

Read more »